Literature DB >> 17722998

Attenuated DNA damage repair by trichostatin A through BRCA1 suppression.

Yin Zhang1, Theresa Carr, Alexandre Dimtchev, Naghmeh Zaer, Anatoly Dritschilo, Mira Jung.   

Abstract

Recent studies have demonstrated that some histone deacetylase (HDAC) inhibitors enhance cellular radiation sensitivity. However, the underlying mechanism for such a radiosensitizing effect remains unexplored. Here we show evidence that treatment with the HDAC inhibitor trichostatin A (TSA) impairs radiation-induced repair of DNA damage. The effect of TSA on the kinetics of DNA damage repair was measured by performing the comet assay and gamma-H2AX focus analysis in radioresistant human squamous carcinoma cells (SQ-20B). TSA exposure increased the amount of radiation-induced DNA damage and slowed the repair kinetics. Gene expression profiling also revealed that a majority of the genes that control cell cycle, DNA replication and damage repair processes were down-regulated after TSA exposure, including BRCA1. The involvement of BRCA1 was further demonstrated by expressing ectopic wild-type BRCA1 in a BRCA1 null cell line (HCC-1937). TSA treatment enhanced radiation sensitivity of HCC-1937/wtBRCA1 clonal cells, which restored cellular radiosensitivity (D(0) = 1.63 Gy), to the control level (D(0) = 1.03 Gy). However, TSA had no effect on the level of radiosensitivity of BRCA1 null cells. Our data demonstrate for the first time that TSA treatment modulates the radiation-induced DNA damage repair process, in part by suppressing BRCA1 gene expression, suggesting that BRCA1 is one of molecular targets of TSA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17722998     DOI: 10.1667/RR0811.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  40 in total

1.  Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.

Authors:  Mandana Namdar; Gisela Perez; Lang Ngo; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-29       Impact factor: 11.205

Review 2.  An overview of epigenetic assays.

Authors:  J Tyson DeAngelis; Woodrow J Farrington; Trygve O Tollefsbol
Journal:  Mol Biotechnol       Date:  2007-10-18       Impact factor: 2.695

Review 3.  Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.

Authors:  Prabhat Singh; Raghuvir Singh Tomar; Srikanta Kumar Rath
Journal:  Mol Biol Rep       Date:  2015-06-02       Impact factor: 2.316

4.  Contribution of decreased expression of Ku70 to enhanced radiosensitivity by sodium butyrate in glioblastoma cell line (U251).

Authors:  Yuhui Li; Hongxia Zhou; Enming Xing; Meera Dassarath; Jinghua Ren; Xiaorong Dong; Hongli Liu; Kunyu Yang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

Review 5.  Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

Authors:  K Ted Thurn; Scott Thomas; Amy Moore; Pamela N Munster
Journal:  Future Oncol       Date:  2011-02       Impact factor: 3.404

6.  Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Authors:  Sai-Wen Tang; Anish Thomas; Junko Murai; Jane B Trepel; Susan E Bates; Vinodh N Rajapakse; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

7.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Authors:  Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

8.  Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.

Authors:  L Stingl; T Stühmer; M Chatterjee; M R Jensen; M Flentje; C S Djuzenova
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

9.  BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.

Authors:  Katherine V Clark-Knowles; Anna M O'Brien; Johanne I Weberpals
Journal:  J Oncol       Date:  2010-02-22       Impact factor: 4.375

10.  Postradiation sensitization of the histone deacetylase inhibitor valproic acid.

Authors:  Prakash Chinnaiyan; David Cerna; William E Burgan; Katie Beam; Eli S Williams; Kevin Camphausen; Philip J Tofilon
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.